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Abstract
Background: Migraine has been associated with cardiovascular disorders. Endothelial dysfunction may be a
mechanism underlying this association. The present study tested the hypothesis that endothelium-dependent
vasodilation, basal endothelial nitric oxide release and endothelial fibrinolytic capacity are impaired in migraine
patients.
Methods: Graded doses of sodium nitroprusside (SNP, 0.2 to 0.8 μg.min
-1.dL
-1 forearm), substance P (0.2 to 0.8
pmol.min
-1.dL
-1 forearm) and N
G-monomethyl-L-arginine (L-NMMA, 0.1 to 0.4 μmol.min
-1.dL
-1 forearm) were infused
into the brachial artery of 16 migraine patients with or without aura during a headache-free interval and 16 age-
and sex-matched subjects without a history of migraine. Forearm blood flow (FBF) was measured by strain-gauge
venous occlusion plethysmography. Local forearm release of tissue plasminogen activator (t-PA) in response to
substance P infusion was assessed using the arteriovenous plasma concentration gradient. Responses to infused
drugs were compared between patients and matched controls by analysis of variance.
Results: In both migraine patients and control subjects, SNP and substance P caused a dose-dependent increase,
and L-NMMA a dose-dependent decrease in FBF (P < 0.001 for all responses). In both groups, substance P caused
an increase in t-PA release (P < 0.001). FBF responses and t-PA release were comparable between migraine patients
and control subjects.
Conclusions: The absence of differences in endothelium-dependent vasodilation, basal endothelial nitric oxide
production and stimulated t-PA release between migraine patients and healthy control subjects argues against the
presence of endothelial dysfunction in forearm resistance vessels of migraine patients.
Background
Migraine is a common neurovascular disorder, charac-
terized by recurrent episodes of headache, dysfunction
of the autonomic nervous system, and in some patients,
an aura involving neurologic symptoms [1]. The patho-
physiology of migraine is largely unknown. During
the last decade, a neurogenic hypothesis of migraine has
largely replaced the classical vascular theory [2]. None-
theless, migraine has been associated with several cardi-
ovascular disorders including ischemic stroke [3],
ischemic heart disease [4], vasospastic disorders [5,6]
and genetically determined vasculopathies [7].
The mechanisms underlying the association between
migraine and cardiovasculard i s o r d e r sa r ec u r r e n t l y
unknown. Migraine has been proposed as an “endothe-
liopathy” [8]. The vascular endothelium regulates
numerous vascular functions [9]. In response to specific
stimuli, endothelial cells secrete local vaso-active media-
tors, including the vasodilator nitric oxide (NO) and
vasoconstrictor endothelin-1 (ET-1) and tissue-type
plasminogen activator (t-PA), which contributes to the
fibrinolytic pathway. Several observations suggest that
endothelial function is abnormal is migraine patients,
including an increased prevalence of anti-endothelial
cell antibodies that may induce endothelial damage [10]
and raised plasma levels of ET-1 [11] and von Willeb-
rand factor [12]. Interestingly, ET-1 has been shown to
produce cortical spreading depression (CSD) in rats
[13]. CSD is considered the biological substrate of the
migraine aura and a trigger for migraine attacks [2].
Although evidence from human studies is currently
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factor may induce a migraine attack.
The aim of the present study was to test the hypoth-
esis that migraine is associated with endothelial dysfunc-
tion. To this end, endothelial function was assessed in
vivo in the human forearm resistance vasculature by
measuring: (1) stimulated endothelial NO release, (2)
basal endothelial NO release and (3) stimulated
endothelial t-PA release.
Methods
Subjects
Migraine patients with or without aura, as defined by
the International Headache Society diagnostic criteria
[14] and control subjects were recruited from hospital
and university staff, university students and the general
population through advertisements. Major exclusion cri-
teria were: age < 18 and ≥ 50 years, body mass index
(BMI) < 18 and ≥ 30 kg.m
-2, history of cardiovascular
disease, smoking, hypertension (systolic blood pressure
> 140 mm Hg or diastolic blood pressure > 90 mm Hg),
diabetes, hypercholesterolaemia (total cholesterol > 6.5
mmol/L), pregnancy or lactation and regular use of
vasoactive drugs (except hormonal contraceptives).
Based on medical history, physical examination, routine
laboratory tests and electrocardiography all participants
were in good health.
The diagnosis of migraine, initially made by a neurolo-
gist or general physician, was confirmed by a validated
questionnaire [15]. Patients with a history of migraine of
< 1 year, > 15 days of headache per month or using
antimigraine drugs > 10 days/month were excluded.
Control subjects without a history of migraine were
matched for gender, age and hormonal contraceptive
use. Control subjects with on average > 1 headache epi-
sode per month, a history of moderate or severe head-
aches or first-degree relatives with a history of migraine
were excluded.
The study was approved by the ethical committee of
the University Hospital and conducted in accordance
with the Declaration of Helsinki. All subjects provided
written informed consent prior to participation.
Experimental conditions
Experiments were performed in the morning after an
overnight fast in a quiet, temperature controlled (23 ±
1°C) room. Female subjects were studied on day 5-12 of
their menstrual cycle (mid follicular phase) or outside
the “pill free” period if taking oral contraceptives. Sub-
jects abstained from any drug (except oral contracep-
tives) for at least 3 days and from alcohol- and caffeine-
containing beverages for at least 24 hours. During the
experimental visit, subjects rested supine on a comforta-
ble bed. Migraine patients were headache free for at
least 72 hours. If a migraine attack ensued within 24
hours after the visit, measurements were repeated in
another headache-free period.
Intra-arterial drug infusion
A catheter (Angiocath® 22G, Beckton Dickinson, Temse,
Belgium) was introduced into the brachial artery of the
non-dominant arm after local anaesthesia with 1 mL of
lidocaine (Xylocaine®, 10 mg/mL, Astra Pharmaceuticals,
Brussels, Belgium). Drugs or saline (NaCl 0.9%) were
infused continuously in a single blind manner using
automated infusion pumps (Ivac® P1000, Ivac Medical
Systems, Eli Lily, Brussel, Belgium) and pressure-resis-
tant polyethylene infusion tubes (Original-Perfusor®, B
Braun, Melsungen, Germany). Doses were normalised to
forearm volume (measured by water displacement) by
maintaining the total rate of intra-arterial infusions con-
stant at 100 μL.min
-1.dL
-1 forearm.
Drugs
Sodium nitroprusside (SNP, David Bull Laboratories,
Warwick, United Kingdom), substance P (Clinalfa, Läu-
felfingen, Switzerland) and N
G-monomethyl-L-arginine
(L-NMMA, Clinalfa, Läufelfingen, Switzerland) were dis-
solved in NaCl 0.9% (B Braun, Melsungen, Germany) on
the day of the experiment and kept at 4°C. SNP solu-
tions were protected from light during the experiment.
Doses were selected based on previous work [16,17].
Forearm blood flow and blood pressure
Forearm blood flow (FBF) was assessed in both the infused
and non-infused arm using strain-gauge venous occlusion
plethysmography [18]. Electrically calibrated mercury-in-
silastic strain gauges (D.E. Hokanson, Bellevue, USA) were
applied at the point of maximal forearm circumference.
The hands were occluded from the circulation during
measurements through rapid inflation of wrist cuffs to 200
mmHg. Wrist cuffs were inflated at least 60 s before start-
ing plethysmographic recordings in order to allow FBF to
stabilize. Upper arm cuffs were intermittently inflated to
40 mmHg for the first 10 s in every 15 s to block tempora-
rily venous return of blood from the forearm and thus
obtain multiple plethysmographic tracings (EC6 Plethys-
mograph, D.E. Hokanson, Bellevue, USA). Analogue vol-
tage output from the plethysmograph was processed by an
analogue-to-digital converter (Powerlab®/8SP, AD Instru-
ments, Castle Hill, Australia) and appropriate software
(Chart® v4.0 for Windows, AD Instruments, Castle Hill,
Australia) and recorded onto a computer (Dell Optiplex®
G1, Dell Computer Corporation, Limerick, Ireland). Cali-
bration was achieved using the internal standard of the
plethysmograph.
Systolic and diastolic blood pressure and heart rate
were measured in the non-infused arm using a validated
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OMRON Healthcare, Hoofddorp, The Netherlands).
Measurements were performed immediately after the
preceding FBF recording (Figure 1).
Blood sampling and assay
Arterial and venous blood samples were obtained at the
end of substance P infusions and the preceding saline infu-
sion (Figure 1). For venous blood sampling, a catheter (20
or 22 G, Insyte-W, Beckton Dickinson, Temse, Belgium)
was inserted into a superficial antecubital vein of the
infused arm. Arterial blood was sampled through the
arterial catheter. Blood (4.5 mL) was collected into ice-
cooled glass tubes containing 0.5 mL 0.105 M sodium
citrate (BD Vacutainer®, Beckton Dickinson, Plymouth,
UK) and kept on ice before being centrifuged at 2500 g for
15 min at 4°C within 1 hour of sampling. Plasma was
transferred to plastic tubes (CryoTube®, Nunc A/S, Ros-
kilde, Denmark) and stored at -80°C until analysis. Plasma
t-PA concentration was determined using an enzyme-
linked immunosorbent assay as previously described [19].
Study protocol (Figure 1)
After arterial cannulation, saline was infused for 30 min
to allow for equilibration. At the end of this infusion,
two FBF measurements (3 min each), were performed.
The mean of these was used as baseline FBF. Three
incremental doses of each drug (SNP at 0.2, 0.4 and 0.8
μg.min
-1.dL
-1 forearm; Substance P at 0.2, 0.4 and 0.8
pmol.min
-1.dL
-1 forearm; and L-NMMA at 0.1, 0.2 and
0.4 μmol.min
-1.dL
-1 forearm) were infused for 6 min at
each dose, separated by at least 12 min of saline infusion
between the different drugs (wash-out). FBF was mea-
sured during the final 3 min of each drug infusion or
wash-out infusion period. The order of drug infusions
was the same for all subjects.
Data analysis and statistics
FBF was determined from the slope of the initial part of
each plethysmographic tracing. Plethysmographic data
were extracted from Chart data files and FBF responses
were calculated for individual plethysmographic tracings
using a template spreadsheet (Microsoft Excel 2000
v9.0, Microsoft Corporation, USA). Tracings unsuitable
for analysis due to motion artefacts were manually
rejected. All tracings were analysed by the same analyst
who was unaware of the subject’s diagnosis. The mean
of the final 5 FBF tracings from each recording period
was used for analysis. The FBF measurement at the end
of the saline infusion preceding each drug infusion was
used as baseline measurement for that particular drug
infusion. FBF responses were expressed as absolute FBF
in ml.min
-1.dL
-1 forearm for SNP and Substance P and
as percentage change from baseline in the FBF-ratio
between infused and non-infused arm for L-NMMA, as
discussed previously [20].
As an estimate of local t-PA release, the product of the
arteriovenous plasma concentration gradient and forearm
plasma flow was calculated: release = (Cv-Ca)×F B F×
[(101-hematocrit)/100], where Cv and Ca are the venous
and arterial plasma concentrations, respectively [21].
Comparison of baseline characteristics between groups
was made by t-test for independent samples. FBF
responses, blood pressure and heart rate were analysed
by repeated measures analysis of variance (ANOVA),
with dose as within subject variable. Comparisons
between groups were made by repeated measures
ANOVA, with dose as within subject variable and group
(migraine or control) as between subject variable. As a
summary measure, the mean difference in FBF response
between groups, expressed as change in FBF from base-
line to the highest infused dose, was calculated together
with the 95% confidence interval (CI). Based on power
calculations using data from previous work [22], the
population size of the present study gives 80% power at
a significance level of 0.05 for detecting a 29% difference
in FBF increase between groups in response to the high-
est dose of Substance P.
All statistical analyses were performed using commer-
cially available software (NCSS 2000, Number Cruncher
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Figure 1 Study protocol. SNP, sodium nitroprusside; L-NMMA, N
G-monomethyl-L-arginine; FBF, forearm blood flow.
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ered statistically significant. Data are presented as mean
± SEM in figures and mean ± SD in tables and text.
Results
No differences in baseline characteristics were observed
between groups (Table 1). Migraine patients had been
suffering from migraine for 5.6 ± 3.3 years. Migraine
with aura was diagnosed in 9 (56%) and migraine with-
out aura in 7 (44%) patients. Migraine attacks occurred
with a frequency of 1.2 ± 0.9 per month and lasted 20 ±
11 hours. As acute anti-migraine drugs, analgesics (para-
cetamol or non-steroidal anti-inflammatory drugs) were
used by 75%, triptans by 13% and metoclopramide by
6% of patients.
Blood pressure, heart rate and FBF in the non-infused
arm did not change during the infusions (data on file;
Table 2).
SNP and Substance P increased FBF in a dose-depen-
dent fashion (Table 2, Figure 2). The FBF responses to
SNP and Substance P were comparable between
migraine patients and controls (P =0 . 4 4a n dP = 0.80,
respectively). The mean differences in FBF response to
SNP and Substance P were 1,8 ml.min
-1.dL
-1 forearm
(95% CI, -2.5 to 6.1) and -0,6 ml.min
-1.dL
-1 forearm
(95% CI -2.8 to 1.6), respectively.
L-NMMA decreased FBF in a dose-dependent fashion
(Table 2, Figure 3). The FBF response to L-NMMA was
comparable between migraine patients and controls (P =
0.50). The mean difference in FBF response to L-
NMMA was 2% (95% CI, -10 to 13).
Venous plasma t-PA levels did not differ between
migraine patients and controls (7,4 ± 11 ng.mL
-1 and 6,5 ±
5.4 ng.mL
-1, respectively, P = 0.86). The basal and stimu-
lated t-PA release were comparable (P =0 . 6 9a n dP =
0.87, respectively) between migraine patients (-0.6 ± 1.1
ng.dL
-1.min
-1 and 7.4 ± 5.5 ng.dL
-1.min
-1) and controls
(-0.6 ± 2.1 ng.dL
-1.min
-1 and 7.1 ± 5.5 ng.dL
-1.min
-1).
Subgroup analyses did not reveal differences between
migraine patients with aura and without aura (data not
shown).
Discussion
In the present study, we compared FBF responses to
SNP, Substance P and L-NMMA between migraine
patients with or without aura and matched individuals
without migraine. In addition, we compared the acute t-
PA release in response to substance P in both groups.
Our findings indicate that several markers of endothelial
function, including the stimulated and basal endothelial
NO release and stimulated endothelial t-PA release, are
not altered in migraine patients in between migraine
attacks.
Endogenous NO is generated by the conversion of the
amino acid L-arginine to citrulline by three different
nitric oxide synthases (NOS). Neuronal and endothelial
NOS are constitutively expressed and produce relatively
small quantities of NO in comparison with the inducible
form of the synthase. Endothelial-derived NO is a key
molecule in vasomotor function. To our knowledge, this
is the first study that assessed the basal endothelial
release of NO in migraine patients, using a non-selective
antagonist of nitric oxide synthase (L-NMMA). The
response to L-NMMA did not differ between patients
with migraine and control subjects, indicating that the
basal endothelial release of NO from peripheral resis-
tance vessels is unaltered in migraine patients, at least
outside the migraine attack period. This does not
exclude that basal NO release from other vascular beds
is altered in the same patients, or that it is impaired pre-
ceding, during or immediately after a migraine attack.
Previous studies measuring metabolites of NO in
Table 1 Baseline subject characteristics
Characteristic Control subjects
(n = 16)
Migraine patients
(n = 16)
P
Age, years 24.0 ± 3.0 24.5 ± 4.0 0.68
Female, n (%) 12 (75) 12 (75) 1.0
Current hormonal contraceptive use, n (% of women) 10 (83) 10 (83) 1.0
Body mass index, kg/m
2 22.6 ± 2.7 22.7 ± 2.3 0.92
Systolic blood pressure, mm Hg 119 ± 8 117 ± 9 0.47
Diastolic blood pressure, mm Hg 70 ± 5 70 ± 7 0.93
Heart rate, bpm 61 ± 10 64 ± 9 0.29
Total cholesterol, mmol/L 4.0 ± 0.8 4.1 ± 0.5 0.72
HDL cholesterol, mmol/L 1.8 ± 0.4 1.7 ± 0.4 0.80
LDL cholesterol, mmol/L 1.9 ± 0.6 1.9 ± 0.6 0.78
Triglycerides, mmol/L 0.8 ± 0.2 0.9 ± 0.4 0.27
Glucose, mmol/L 4.4 ± 0.2 4.5 ± 0.3 0.81
Forearm volume, mL 919 ± 146 855 ± 154 0.24
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gested a basal hyperactivity of the L-arginine-NO path-
way [23-25]. Our findings suggest that, if basal NO
production is indeed increased in migraine patients,
other NO synthases than endothelial NOS in extracra-
nial vessels are implicated.
NO induces vasodilation through a direct action on
the vascular smooth muscle cell. A recent study in
patients with migraine without aura, showed an
impaired FBF response to the NO donor SNP, leading
the authors to the hypothesis that vascular smooth mus-
cle cell function is impaired in migraine without aura
[26]. In contrast to these findings, we observed a com-
parable vasodilator response to SNP between patients
with migraine and controls, which is in agreement with
a previous, smaller study by our group [27]. A small
study in patients with migraine without aura also
s h o w e dan o r m a lr e s p o n s et oS N Po ft h ec u t a n e o u s
microcirculation measured by laser Doppler flowmetry
[28]. Adding more complexity are findings from pre-
vious work in patients with migraine without aura show-
ing an increased vasodilator response to another NO
donor, nitroglycerin, of the brachial artery [29] or intra-
cranial blood vessels [30], suggesting an arterial hyper-
sensitivity to NO. Thus, existing data are clearly
inconsistent, which may be explained by differences in
patient characteristics (longstanding migraine or
migraine of recent onset; migraine with or without aura)
or differences in the vascular beds studied (micro- or
macrovascular beds, conduit or resistance arteries; intra-
cranial or extracranial arteries).
Several studies have evaluated endothelial function in
patients with migraine. The present study confirms the
findings of a previous, smaller study by our group (n =
10, 1 patient with aura) that showed no difference in
FBF response to serotonin, which releases NO through
Table 2 Forearm blood flow
Control subjects (n = 16) Migraine patients (n = 16)
Sodium nitroprusside dose, μg.min
-1.dL
-1 forearm 0 0.2 0.4 0.8 0 0.2 0.4 0.8
non-infused arm 2.0 ± 0.9 1.9 ± 0.7 1.8 ± 0.8 1.8 ± 0.8 2.0 ± 0.5 2.0 ± 0.6 2.1 ± 0.8 1.9 ± 0.6
infused arm 2.0 ± 0.5 8.6 ± 3.5 10.9 ± 4.2 14.5 ± 5.9* 2.1 ± 0.5 8.7 ± 2.9 12.1 ± 4.6 16.5 ± 6.2*
Substance P dose, pmol.min
-1.dL
-1 forearm 0 0.2 0.4 0.8 0 0.2 0.4 0.8
non-infused arm 1.8 ± 0.8 1.8 ± 0.7 1.8 ± 0.7 1.9 ± 0.8 2.0 ± 0.6 1.9 ± 0.6 2.1 ± 0.6 2.0 ± 0.6
infused arm 2.2 ± 0.7 5.5 ± 2.2 6.9 ± 2.5 8.7 ± 3.8* 2.5 ± 0.7 5.1 ± 1.2 6.5 ± 1.8 8.4 ± 2.5*
L-NMMA dose, μmol.min
-1.dL
-1 forearm 0 0.1 0.2 0.4 0 0.1 0.2 0.4
non-infused arm 1.7 ± 0.5 1.8 ± 0.7 1.9 ± 0.9 1.9 ± 0.8 2.1 ± 0.5 1.9 ± 0.6 2.1 ± 0.6 2.4 ± 0.8
infused arm 2.0 ± 0.5 1.7 ± 0.4 1.6 ± 0.4 1.4 ± 0.4* 2.5 ± 0.6 2.0 ± 0.5 1.9 ± 0.6 1.9 ± 0.6*
Data are expressed as absolute blood flows (ml.min
-1.dL
-1 forearm); *P < 0.001 (ANOVA)
Substance P (pmol.min
-1.dL
-1 forearm)
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Figure 2 Forearm blood flow (FBF) response to sodium nitroprusside (A) and substance P (B) in migraine patients (closed circles) and
control subjects (open circles). P < 0.001 for all responses.
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Page 5 of 8endothelial receptors [27]. A recent study in patients
with migraine without aura (n = 12) assessed endothe-
lial-dependent vasodilation by measuring FBF responses
to acetylcholine [26]. Compared to healthy controls, FBF
response to acetylcholine was impaired, but as FBF
response to SNP, i.e endothelial-independent vasodila-
tion, was impaired while acetylcholine-induced release
of NO was intact, the authors hypothesized that vascular
smooth muscle cell, but not endothelial cell function is
impaired in migraine without aura. A small study in
patients diagnosed with migraine without aura (n = 9)
showed a normal dermal blood flow response to acetyl-
choline measured by laser Doppler flowmetry [28]. Two
small studies (n ≤ 1 0 )d i dn o to b s e r v ead i f f e r e n c ei n
flow-mediated dilation (FMD), a measure of endothe-
lium-dependent vasodilation, between patients and con-
trols [27,31]. However, these studies were likely
underpowered, considering the large variability of FMD
measurements [32]. Recently, a larger study (n = 45)
and a smaller follow-up study (n = 24) observed a
decreased brachial FMD in patients without aura
[29,33]. An impaired FMD was also shown by our group
in a group of patients with migraine with or without
aura of recent onset (n = 50) [34]. In contrast, a study
in patients with migraine with and without aura (n =
50) did not find a difference in FMD between patients
with migraine and controls and between patients with
migraine with aura (n = 25) and without aura (n = 25)
[35]. Taken together, results are clearly inconsistent.
The discrepancies between studies may be related to
heterogeneity in study population, differences in vascu-
lar beds studied and differences in applied endothelial
stimulus.
Previous work in patients with migraine suggested
abnormalities of haemostasis, including abnormal plate-
let function, antiphospholipid antibodies and congenital
thrombophilia, which may cause increased thrombotic
risk in these patients [36]. The endogenous fibrinolytic
system and, in particular, the acute release of t-PA from
the endothelium protects the circulation from intravas-
cular thrombosis. We assessed the acute fibrinolytic
capacity of the endothelium by stimulating the endothe-
lial release of t-PA using intra-arterial infusion of sub-
stance P [21]. No difference was observed in the
forearm t-PA release between migraine patients and
control subjects, suggesting that endothelial fibrinolytic
capacity is normal in migraine patients during a head-
ache-free interval. A larger cross-sectional study
observed an increased plasma t-PA concentration in
young women with (n = 61) and without (n = 64) aura
compared to control subjects [37].
The present study has several limitations. First,
because of the invasive nature of the forearm model, a
relatively small number of subjects was included. In
addition, the FBF response to Substance P in the present
study was 2 times lower than expected from previous
work [22] on which power calculations were based.
Therefore, it cannot be excluded that the present study
was insufficiently powered to detect small, but clinically
relevant differences between migraine patients and con-
trol subjects, in particular between migraine subgroups.
Interestingly, recent prospective studies suggest that
patients with migraine with aura, but not without aura,
are at increased risk for cardiovascular events [4,38].
Therefore, additional studies in migraine subpopulations
with sufficient power are needed. Second, although the
forearm model serves as a convenient model for study-
ing endothelial function, measurement of coronary and
cerebrovascular endothelial function is likely to be of
greatest clinical relevance, as the forearm vascular bed is
less susceptible to atherosclerosis and subsequent
thrombosis. Nevertheless, consistent findings between
the peripheral and coronary circulation support the
notion that the forearm model is a reasonable surrogate
[39]. Studies comparing endothelial function in cerebral
and peripheral vascular beds in the same patients are
lacking. Third, endothelial fibrinolytic capacity depends
on the balance between endothelial release of t-PA and
plasminogen activator inhibitor type 1 (PAI-1) [21]. As
no measurements of PAI-1 or t-PA activity were per-
formed in our study, we cannot completely rule out an
impaired endothelial fibrinolytic activity in patients with
migraine. Finally, regarding the hypothesis of an
endothelial trigger for a migraine attack, we cannot
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monomethyl-L-arginine (L-NMMA) in migraine patients (closed
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in the cranial circulation.
Conclusions
In conclusion, the absence of differences in endothe-
lium-dependent vasodilation, basal endothelial nitric
oxide production and stimulated t-PA release between
migraine patients and healthy control subjects argues
against the presence of endothelial dysfunction in fore-
arm resistance vessels of migraine patients.
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